1. Home
  2. BTAI vs RAY Comparison

BTAI vs RAY Comparison

Compare BTAI & RAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • RAY
  • Stock Information
  • Founded
  • BTAI 2017
  • RAY 1993
  • Country
  • BTAI United States
  • RAY Hong Kong
  • Employees
  • BTAI N/A
  • RAY N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • RAY Consumer Electronics/Appliances
  • Sector
  • BTAI Health Care
  • RAY Consumer Discretionary
  • Exchange
  • BTAI Nasdaq
  • RAY Nasdaq
  • Market Cap
  • BTAI 28.7M
  • RAY 24.7M
  • IPO Year
  • BTAI 2018
  • RAY 2024
  • Fundamental
  • Price
  • BTAI $0.36
  • RAY $1.41
  • Analyst Decision
  • BTAI Strong Buy
  • RAY
  • Analyst Count
  • BTAI 4
  • RAY 0
  • Target Price
  • BTAI $5.00
  • RAY N/A
  • AVG Volume (30 Days)
  • BTAI 949.6K
  • RAY 19.1K
  • Earning Date
  • BTAI 11-14-2024
  • RAY 12-24-2024
  • Dividend Yield
  • BTAI N/A
  • RAY N/A
  • EPS Growth
  • BTAI N/A
  • RAY 57.91
  • EPS
  • BTAI N/A
  • RAY 0.08
  • Revenue
  • BTAI $2,276,000.00
  • RAY $8,557,732.00
  • Revenue This Year
  • BTAI $164.86
  • RAY N/A
  • Revenue Next Year
  • BTAI $69.74
  • RAY N/A
  • P/E Ratio
  • BTAI N/A
  • RAY $17.01
  • Revenue Growth
  • BTAI 83.25
  • RAY 47.13
  • 52 Week Low
  • BTAI $0.35
  • RAY $1.11
  • 52 Week High
  • BTAI $4.17
  • RAY $6.04
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 32.49
  • RAY N/A
  • Support Level
  • BTAI $0.35
  • RAY N/A
  • Resistance Level
  • BTAI $0.52
  • RAY N/A
  • Average True Range (ATR)
  • BTAI 0.06
  • RAY 0.00
  • MACD
  • BTAI -0.00
  • RAY 0.00
  • Stochastic Oscillator
  • BTAI 2.92
  • RAY 0.00

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About RAY Raytech Holding Limited Ordinary Shares

Raytech Holding Ltd is principally engaged in product designing and manufacturing of various product ranges such as Hair Care, Men's Care and Women's Care products. It has sourced and wholesaled a wide range of personal care electrical appliances, which can be broadly classified into seven categories: hair styling series, including hair dryer, hair straightener and curling iron; trimmer series, including facial shaver, nose trimmer and eyebrow trimmer; eyelash curler; neck care series; nail care series; tooling and other personal care appliances such as body and facial brush, reset brush, callus remover, sonic peeling, handy fan and others. Raytech manufactures products under OEM and ODM.

Share on Social Networks: